Difference between revisions of "Ramucirumab (Cyramza)"
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGF inhibitors" to "Category:VEGFR inhbitors") |
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGFR inhbitors" to "Category:VEGFR inhibitors") |
||
| Line 35: | Line 35: | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:Anti-VEGFR antibodies]] | [[Category:Anti-VEGFR antibodies]] | ||
| − | [[Category:VEGFR | + | [[Category:VEGFR inhibitors]] |
[[Category:Bladder cancer medications]] | [[Category:Bladder cancer medications]] | ||
Revision as of 21:20, 2 February 2018
General information
Class/mechanism: Recombinant human IgG1 monoclonal antibody, VEGFR2 (vascular endothelial growth factor receptor 2) antagonist. Ramucirumab binds VEGFR2 and blocks VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D, which inhibits angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ramucirumab (Cyramza) patient drug information (Chemocare)[4]
- Ramucirumab (Cyramza) package insert[1]
- Ramucirumab (Cyramza) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 4/21/2014: FDA approved "for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum- containing chemotherapy."
- 11/5/2014: FDA approval and indication expanded "for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma."
- 12/12/2014: FDA approved "for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy."
- 4/24/2015: FDA approved "in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine."
Also known as
- Code names: IMC-1121B, LY3009806
- Brand name: Cyramza